Table of Contents
Historical Data, Premium Insights, Market Dynamic, Analysis and Projection, By Product, Analysis and Projection, By Application, Analysis and Projection, By End-Use, Analysis and Projection, By Regional Analysis, Competitive Landscape, Company Profiles, Market Revenue, Sale & Price Analysis
Related Topics
Metro Trains Pantographs Market Size Mushroom Extracts Market Size Automotive Electrical Products Market Size Crime Risk Report Market SizeGlobal Diabetic Foot Ulcer Biologics Market Size To Exceed USD 16.76 Billion By 2033
According to a research report published by Spherical Insights & Consulting, The Global Diabetic Foot Ulcer Biologics Market Size is Expected to Grow from USD 9.10 Billion in 2023 to USD 16.76 Billion by 2033, at a CAGR of 6.30% during the forecast period 2023-2033.
Browse 210 market data Tables and 45 Figures spread through 190 Pages and in-depth TOC on the Global Diabetic Foot Ulcer Biologics Market Size, Share, and COVID-19 Impact Analysis, By Product (Skin Substitutes and Growth Factors), By Indication (Neuro-ischemic Ulcers and Neuropathic Diabetic Foot Ulcer), By End Ucser (Hospitals and Clinics), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033.
The global diabetic foot ulcer biologics market refers to the industry that includes the creation, manufacturing, and marketing of biologic therapies such as skin replacements, growth factors, and stem cell therapies that are intended to aid diabetic patients in mending wounds. The need for innovative, efficient treatments for reducing ulcer-related concerns and the rising prevalence of diabetes, and also growing sedentary working schedule, which boosts the market growth. Key driving factors for the growth of the diabetic foot ulcer biologics market include the increasing prevalence of diabetic foot ulcers, an unfortunate consequence that is associated with infections, amputations, and higher mortality, as a result of a worldwide increase in diabetes prevalence. The need for efficient treatment substitutes is further driven by the aging population, which is more susceptible to metabolic disorders and chronic wounds. However, a lack of awareness regarding biologic medicines, high treatment costs, and restricted accessibility in developing countries are the primary barriers preventing the broad use of biologics to treat diabetic foot ulcers.
The skin substitutes segment accounted for the largest revenue share in 2023 and is projected to grow at a significant CAGR during the forecast period.
On the basis of product, the global diabetic foot ulcer biologics market is divided into skin substitutes and growth factors. Among these, the skin substitutes segment accounted for the largest revenue share in 2023 and is projected to grow at a significant CAGR during the forecast period. The segment growth is attributed to the increasing amount of money biotechnology businesses have spent on research and development to provide novel and more effective biologic medications. This is accelerating market expansion, in addition to regulatory assistance and rapid product approvals.
The neuro-ischemic ulcers segment accounted for the highest revenue share in 2023 and is anticipated to grow at a substantial CAGR during the forecast period.
On the basis of indication, the global diabetic foot ulcer biologics market is divided into neuro-ischemic ulcers and neuropathic diabetic foot ulcer. Among these, the neuro-ischemic ulcers segment accounted for the highest revenue share in 2023 and is anticipated to grow at a substantial CAGR during the forecast period. The segment growth can be attributed to increasing research on biologics, such as NovoSorb BTM, in the management of neuro-ischemic ulcers, promoting development, enhancing healing in patients with nerve damage and prohibited blood flow, and minimizing consequences.
The hospitals segment accounted for the largest market share in 2023 and is anticipated to grow at a remarkable CAGR during the forecast period.
On the basis of end user, the global diabetic foot ulcer biologics market is divided into hospitals and clinics. Among these, the hospitals segment accounted for the largest market share in 2023 and is anticipated to grow at a remarkable CAGR during the forecast period. The segment growth is driven increasing number of foot ulcer hospitalizations in addition to comorbidities linked to diabetes. This development raises the demand for biologic treatments in hospital settings, which promotes segment expansion and improved outcomes for patients.
North America is anticipated to hold the largest share of the global diabetic foot ulcer biologics market over the predicted timeframe.
North America is anticipated to hold the largest share of the global diabetic foot ulcer biologics market over the predicted timeframe. The regional market growth can be attributed to the increasing awareness of advanced wound care and significant innovation from top biotech organizations. The adoption of biologics is additionally boosted by clinical trials such as BioStem's BR-AM-DFU, which significantly enhances diabetic foot ulcer therapy effectiveness.
Asia Pacific is expected to grow at the fastest CAGR in the global diabetic foot ulcer biologics market during the forecast period. The regional market growth is driven by the increasing clinical trials and collaborations between regional biotech companies and global healthcare organizations. Innovation is encouraged, and product approvals emerge more rapidly. Further encouraging market acceleration is increasing medical tourism and more reasonably priced alternatives to treatment.
Company Profiling
Major vendors in the global diabetic foot ulcer biologics market are Organogenesis Holdings Inc., Tissue Regenix, BioTissue, Integra LifeSciences, MIMEDX Group, Inc., Convatec Inc., Coloplast Group (Kerecis), Biocomposites, Smith+Nephew, Inc., Stedical Scientific, Inc., Zimmer Biomet, GUNZE LIMITED, and Others.
Key Target Audience
Recent Development
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global diabetic foot ulcer biologics market based on the below-mentioned segments:
Global Diabetic Foot Ulcer Biologics Market, By Product
Global Diabetic Foot Ulcer Biologics Market, ByIndication
Global Diabetic Foot Ulcer Biologics Market, By End User
Global Diabetic Foot Ulcer Biologics Market, Regional
Jun 2025 - The Global Furandicarboxylic Acid Market Size is Expected to Grow from USD 786.4 Million in 2023 to USD 8682.9 Million by 2033, at a CAGR of 27.15% during the forecast period 2023-2033
Jun 2025 - The Global Soil Stabilization Market Size is Expected to Grow from USD 29.89 Billion in 2023 to USD 49.65 Billion by 2033, at a CAGR of 5.21% during the forecast period 2023-2033.
Jun 2025 - The Global Alpha Olefin Market Size is Expected to Grow from USD 9.85 Billion in 2023 to USD 16.72 Billion by 2033, at a CAGR of 5.43% during the forecast period 2023-2033.
We have received your message and would like to thank you for writing to us. If your inquiry is urgent, please use the telephone number listed below to talk to one of our staff members. Otherwise, we will reply by email as soon as possible.
+1 303 800 4326 +91 9561448932 emailsales@sphericalinsights.com
